Pfizer's Omicron Vaccine to Be Ready in March
- 2 years ago
Pfizer's Omicron Vaccine , to Be Ready in March.
CNBC reports Pfizer CEO Albert Bourla
says the company's Omicron-specific
vaccine is almost ready.
This vaccine will be ready in March. , Albert Bourla, CEO Pfizer, via CNBC.
Pfizer has reportedly crafted its newest coronavirus vaccine to target other variants currently circulating the world.
Though it remains unclear if an updated vaccine will be necessary, the company
says they'll be ready regardless.
Though it remains unclear if an updated vaccine will be necessary, the company
says they'll be ready regardless.
The hope is that we will achieve something that will have way, way better protection particularly against infections.., Albert Bourla, CEO Pfizer, via CNBC.
Recent studies conducted by the United Kingdom Health Security Agency found Pfizer and Moderna's two-dose vaccine regimen wanes dramatically after 20 weeks.
Recent studies conducted by the United Kingdom Health Security Agency found Pfizer and Moderna's two-dose vaccine regimen wanes dramatically after 20 weeks.
Regarding Omicron, current vaccines
after two doses are around 10% effective
in preventing symptomatic infection.
However, health officials say the first two doses are still effective in protecting against severe illness and hospitalization.
The study found that the most protected against Omicron were those who had
received a booster shot.
Data shows that boosters are nearly
75% effective in preventing symptomatic cases of COVID-19.
Data shows that boosters are nearly
75% effective in preventing symptomatic cases of COVID-19
CNBC reports Pfizer CEO Albert Bourla
says the company's Omicron-specific
vaccine is almost ready.
This vaccine will be ready in March. , Albert Bourla, CEO Pfizer, via CNBC.
Pfizer has reportedly crafted its newest coronavirus vaccine to target other variants currently circulating the world.
Though it remains unclear if an updated vaccine will be necessary, the company
says they'll be ready regardless.
Though it remains unclear if an updated vaccine will be necessary, the company
says they'll be ready regardless.
The hope is that we will achieve something that will have way, way better protection particularly against infections.., Albert Bourla, CEO Pfizer, via CNBC.
Recent studies conducted by the United Kingdom Health Security Agency found Pfizer and Moderna's two-dose vaccine regimen wanes dramatically after 20 weeks.
Recent studies conducted by the United Kingdom Health Security Agency found Pfizer and Moderna's two-dose vaccine regimen wanes dramatically after 20 weeks.
Regarding Omicron, current vaccines
after two doses are around 10% effective
in preventing symptomatic infection.
However, health officials say the first two doses are still effective in protecting against severe illness and hospitalization.
The study found that the most protected against Omicron were those who had
received a booster shot.
Data shows that boosters are nearly
75% effective in preventing symptomatic cases of COVID-19.
Data shows that boosters are nearly
75% effective in preventing symptomatic cases of COVID-19